中国当代医药2025，Vol.32Issue(9)：7-10,17,5.DOI:10.3969/j.issn.1674-4721.2025.09.01
细胞周期蛋白依赖激酶5抑制剂通过调控转录与雄激素受体辅助因子在前列腺癌治疗中潜在机制的研究
Cyclin dependent kinase 5 inhibitors regulate transcription and andrgen receptor cofactors in the treatment of prostate cancer potential mechanisms
摘要
Abstract
Objective To investigate the potential mechanism of cyclin dependent kinase 5(CDK5)inhibitors in prostate cancer therapy by regulating transcription and androgen receptor(AR)cofactors.Methods Eighty human prostate cancer cell lines DU 145 were selected as the study object,and they were divided into CDK5 inhibitor group(n=40)and control group(n=40)according to different cell treatment methods.CDK5 siRNA interfered with the expression of CDK5 in DU145 cells in the CDK5 inhibitor group,while no special treatment was given to the control group.The growth inhibition rate of CDK5 inhibitors on castration-resistant prostate cancer cell line DU 145 was analyzed,and the expression levels of zinc finger E-box binding homeobox 1(Zeb1),Vimentin and AR protein were compared between the two groups.Results The growth inhibition rate of castration-resistant prostate cancer cell line DU145 in CDK5 inhibitor group at 24 h was lower than that at 48 and 72 h,the differences were statistically significant(P＜0.05).The growth inhibition rate of CDK5 inhibitor group was higher than that of control group at 24,48 and 72 h,and the differences were statistically significant(P＜0.05).The proteins of Zeb1,Vimentin and AR in CDK5 inhibitor group were lower than those in control group,and the differences were statistically significant(P＜0.05).Conclusion The decreased activity and expression levels of CDK5 and AR can in-hibit the metastasis,invasion and malignant proliferation of castration-resistant prostate cancer cells DU145 through Vimentin/Zeb1 signaling pathway.关键词
细胞凋亡/转移侵袭/前列腺癌/雄激素受体/细胞周期蛋白依赖激酶5Key words
Cell apoptosis/Metasis and invasion/Prostate cancer/Androgen receptor/Cyclin dependent kinase 5分类
临床医学引用本文复制引用
滕志武,张中伟,张健平,罗丽华,方俊..细胞周期蛋白依赖激酶5抑制剂通过调控转录与雄激素受体辅助因子在前列腺癌治疗中潜在机制的研究[J].中国当代医药,2025,32(9):7-10,17,5.基金项目
江西省卫生健康委科技计划项目(202311556). （202311556）
